01—Abstract
Summary
Summary of the 8-K filed April 27, 2026. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. (PFE) held its Annual Meeting of Shareholders on April 23, 2026, with the key outcomes being the election of its Board of Directors and the ratification of its independent auditor.
All nominated directors received a substantial majority of "For" votes, indicating strong shareholder confidence in the current leadership. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was overwhelmingly approved. Shareholders also approved the amended Pfizer Inc. 2019 Stock Plan and, on an advisory basis, the compensation of the Named Executive Officers.
However, a shareholder proposal to adopt an Independent Chair Policy was not approved, signaling that the majority of shareholders prefer the current board structure. These outcomes reflect a generally supportive shareholder base for Pfizer's governance and executive compensation practices.
02—Key points
Key Highlights
- All incumbent directors were re-elected to the Board with strong "For" vote majorities.
- KPMG LLP was ratified as Pfizer's independent registered public accounting firm for the 2026 fiscal year with significant shareholder approval.
- The amended Pfizer Inc. 2019 Stock Plan was approved by shareholders.
- Shareholders provided advisory approval for the compensation of Named Executive Officers.
- A shareholder proposal to Adopt An Independent Chair Policy was not approved.
- The Annual Meeting of Shareholders took place on April 23, 2026.
03—Questions
Frequently Asked Questions
Were all the company's directors re-elected?
Yes, all nominees for election to the Company's Board of Directors were elected, with substantial "For" votes supporting each nominee.
What was the outcome of the vote on the independent auditor?
Shareholders overwhelmingly approved the selection of KPMG LLP as the Company's independent registered public accounting firm for the 2026 fiscal year.
Did shareholders approve the stock plan and executive compensation?
Yes, shareholders approved the amended Pfizer Inc. 2019 Stock Plan and also approved, on an advisory basis, the compensation of the Company's Named Executive Officers.
Was the shareholder proposal for an Independent Chair Policy successful?
No, the shareholder proposal to Adopt An Independent Chair Policy was not approved by the shareholders.
04—Continue